February 20-21 2019

LinkedIn Logo

2018 Speakers

Expand/Collapse

Jason Wright
Director of Molecular Biology and Genomics
Homology Medicines Inc.

Jacinthe Gingras
Associate Director of Ophthalmology and Neurology
Homology Medicines, Inc.

Richard Margolin
Executive Director, Clinical Neuroscience
Pfizer

Susan Rosenbaum
Founder, Chairman & Chief Executive Officer
Lauren Sciences LLC

Alexandre Akoulitchev
Chief Scientific Officer and Co-Founder
Oxford BioDynamics

Day Two

Thursday, February 22nd, 2018

13.30 | Multi-Center Biomarker Development for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis

14.30 | Session Q&A Panel

Tony Altar
CSO
Verge Genomics

Brad Margus
Co-founder & CEO
Cerevance

Brendon Boot
Medical Director
Voyager Therapeutics

Damian Crowther
Director, R&D Neuroscience IMED Biotech Unit
AstraZeneca

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

08.50 | Shedding Light on the Role of TREM2 in Alzheimer’s Disease

Douglas Bonhaus
CSO
Neuropore Therapeutics

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

16.00 | Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease

Douglas Galasko
Professor, Department of Neurosciences
University of California, San Diego

Day Two

Thursday, February 22nd, 2018

14.30 | Session Q&A Panel

14.10 | Biomarker Data in Cerebrospinal Fluid in Parkinson’s Disease: The PPMI Study

Jan Torleif Pedersen
Director, TBL Alzheimers Disease and Dementia
Neurodegeneration, H. Lundbeck A/S

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.50 | Development of Phospo-Tau Antibodies Targeting Pathologic Forms of Tau

Jay Schneider
Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit
Thomas Jefferson University

Day One

Wednesday, February 21, 2018

16.30 | Evaluating Translatability: Relevance of Rodent & Nonhuman Primate Preclinical Models of Cognitive Impairment to Clinical Drug Development

17.30 | Session Q&A Panel

Johan Luthman
Vice President, Neuroscience Business Group
Eisai Pharmaceuticals

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.00 | Perspectives on Biomarker Applications Through Drug Development

Jonathan Brotchie
Co-Founder and Chairman
Atuka Inc.

Day One

Wednesday, February 21, 2018

17.30 | Session Q&A Panel

16.50 | Translational Value of Non-Human Primate Models of Motor Impairment and Disease Progression in Parkinson’s Disease

Jonathan Levenson
Senior Director, Preclinical Research & Development
Proclara Biosciences

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.20 | Developing Preclinical Biomarkers of Proteopathic Seeds in Neurodegenerative Disease

Krzysztof Wicher
Principal Scientist and Group Leader
Ossianix

Larry Brown
Executive Vice President R&D, Chief Scientific Officer
Noveome Biotherapeutics

Laurent Bogdanik
Senior Study Director; Lead Scientist in Neurobiology
The Jackson Laboratory

 

Martin Tolar
Founder, President & CEO
Alzheon, Inc

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.30 | The Amyloid Cascade Hypothesis: The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Massimiliano Bianchi
General Manager & Scientific Director
Transpharmation Ltd

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

09.10 | The Importance of Microtubular Proteins & Cytokines in Neuroplasticity & Neuroinflammation

Ottavio Vitolo
VP Clinical Development
Homology Medicines Inc

Workshop A

Tuesday, February 20

08.00 | Exploring the Application of Gene Editing in the Treatment of CNS Disorders

Patrice Garnier
CEO
Amabiotics

Workshop C

Tuesday, February 20

15.00 | The Gut-Brain Axis: The Microbiome as a Versatile Target for Neurodegenerative Disease

Ping Chiao
Senior Director
Biogen

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.20 | Amyloid PET Imaging in Aducanumab Ph1b PRIME study

Richard Ransohoff
Entrepreneur In Residence
Third Rock Venture

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

08.30 | (Re) Introduction to Microglia as Intrinsic Brain Cells

Richard Wade-Martins
Professor Molecular Neuroscience
University of Oxford

Richard Wyse
Director of Research & Development
The Cure Parkinson's Trust

Day One

Wednesday, February 21, 2018

08.25 | Chairs Welcoming & Opening Remarks

Day Two

Thursday, February 22nd, 2018

08.25 | Chairs Opening Remarks

Thom Tulip
Senior Advisor
Cerveau Technologies, Inc.

Day Two

Thursday, February 22nd, 2018

11.40 | Presentation to Be Confirmed

Robert C. Switzer
Founder & Scientific Director
NeuroScience Associates

Day One

Wednesday, February 21, 2018

16.00 | Presentation Title To Be Confirmed

S. Pablo Sardi
R&D Director
Sanofi-Genzyme

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.40 | The Role of GBA in Lysosomal Function, Neuroprotection and Progression in Parkinson’s Disease

Samuel Hasson
Principal Investigator, Neuroscience
Pfizer

Workshop B

Tuesday, February 20

11.30 | The Promise & Challenge of Neuroimmune Therapeutics: Targets, Models, and the Science Behind the Innate Immune System’s Role in Neurodegenerative Disease

Susan Browne
Director
Teva Pharmaceuticals

Tamara Maes
CSO and VP
Oryzon Genomics S.A

Thomas Skøt Jensen
CEO & Co-founder
Intomics

Day Two

Thursday, February 22nd, 2018

09.10 | Precision Medicine in a Data-rich Era – Challenges and Successful Bioinformatics Approaches

09.30 | Session Q&A Panel

Nikolai Naryshkin
Executive Director, Biology – Genetic Disorders
PTC Therapeutics, Inc.